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Epidermal transglutaminase-K is believed to catalyze the co-
valent linking ofloricrin and involucrin to form cross-linked 
(CE) envelopes . . In normal skin, transglutaminase-K is ex-
pressed as a band immediately below the stratum corneum, 
whereas in psoriasis and healing skin its expression is consid-
erably expanded throughout the suprabasallayers. We have 
IUvestigated whether the hyperproliferative state induced by 
short-term application of topical retinoic acid is similarly 
characterized by an increase in transglutaminase-K enzyme 
activity and immunoreactivity. 
Retinoic acid (0.1 % cream) or vehicle were applied to 
human skin and occluded for 4 d. Skin biopsies were obtained 
for measurement of transglutaminase-K and transglutamin-
ase-C activity and immunoreactivity. For comparison, cul-
tured normal human keratinocytes were incubated for 4 din 
the presence of 1 11M retinoic acid and the subsequent trans-
glutaminase-K activity and immunoreactivity measured. 
Tr~nsglutaminase-K activity was increased 2.8 times in reti-
nOtc acid compared to vehicle-treated skin (p < 0.005, n = 
12) whereas there was no significant difference in transgluta-
minase-C activity. However, transglutaminase-K mRNA 
levels were not significantly different between retinoic acid-
and vehicle-treated skin. In vehicle-treated skin, transgluta-
minase-K immunoreactivity was limited to a narrow, sub-
stratum corneal band, but was considerably expanded in a 
diffuse suprabasal pattern in retinoic acid - treated epidermis. 
In contrast, transglutaminase-K immunostaining was de-
creased and its enzymatic activity reduced sixfold)in retinoic 
acid-treated keratinocytes (p < 0.01, n = 4). 
These results demonstrate that retinoic acid treatment in 
vivo, in contrast to in vitro, leads to not only increased 
transglutaminase-K protein expression but also increased en-
zymatic activity in the absence of detectable increases in 
mRNA levels. These data, taken with the previously re-
ported lack of in vivo modulation of the differentiation 
markers keratins 1 and 10 by retinoic acid, indicate that cer-
tain aspects of keratinocyte terminal differentiation that are 
altered in vitro by retinoic acid do not occur in vivo in human 
skin. ] Invest Dermatol 99:283 -288, 1992 
---------------------------------------------------------------------------------------------------------
T he transglutaminases (Tgase) are calcium and sulfhy-dryl-dependent enzymes that modify proteins by forming covalent e-(gamma-glutamyl) lysine cross-links [1]. To date, three types of Tgase have been  described in epidermis including cytosoluble, pro-
~ase E [2,3], membrane-bound keratinocyte-specific transgluta-
trlinase (Tgase-K) [4-6], also termed type I or epidermal, and the 
cytosoluble tissue-type transglutaminase (Tgase C) or type II [7]. 
h A prominent feature of keratinocyte terminal differentiation is 
t e formation of a highly insoluble, cross-linked envelope (CE) 
immediately beneath the keratinocyte plasma membrane [8,9]. The 
production ofkeratinocyte CE is catalyzed by Tgase-K (and perhaps 
Tgase E), which cross-links the precursor proteins involucrin 
[10,11], loricrin [12], and keratolinin [13] via the formation of 
e-(gamma-glutamyl) lysine isopeptide bonds. Using both immuno-
histochemical and monoclonal antibody techniques, Tgase-K and 
its substrate involucrin have been demonstrated in the upper layers 
of normal er.idermis, situated immediately below the stratum cor-
neum [4,14 . This finding is consistent with other markers of epi-
dermal terminal differentiation such as keratins 1 and 10 [15]. 
----------------------------------------------------------------------------------------------------------
28Manuscript received September 11, 1991; accepted for publication March 
,1992. 
t Supported in part by the R.W. Johnson Pharmaceutical Research Insti-
t~;e, Raritan, NJ, the Babcock Dermatologic Endowment, and the Derma-
ogy Foundation (AA). 
D Reprint requests to: Dr. C.E.M. Griffiths, Department of Dermatology, 
A. blversity of Michigan Medical Center, 1910 Taubman Center, Ann 
rp or, Michigan 48109-0314. 
D resented in part at the annual meeting of the Society for Investigative 
ermatology, Seattle, WA, May 3, 1991. 
Abbreviations: 
CE: cross-linked envelope 
CRABP-II: cellular retinoic acid - binding protein-II 
DMSO: dimethyl sulfoxide 
EDTA: ethylenediaminetetraacetic acid 
PBS: phosphate-buffered saline 
RA: retinoic acid 
Tgase: transglutaminase 
Tgase-C: tissue type transglutaminase 
Tgase-K: keratinocyte-specific transgluraminase 
0022-202Xj92jSOS.00 Copyright © 1992 by The Society for Investigative Dermatology, Inc. 
283 
284 GRIFFITHS ET AL 
When added to keratinocytes in vitro, retinoic acid (RA) reduces 
Tgase-K activity and as a consequence may inhibit terminal differ-
entiation and concomitant CE formation [16]. Paradoxically, RA is 
known to induce epidermal hyperproliferation and increased 
Tgase-K immunoreactivity when applied topically to normal 
human skin for 4 months in the treatment of photodamage [17] or 
for 4 d under occlusion [18]. Although epidermal Tgase-Kimmuno-
reactivity is increased after application of RA, it is not known 
whether this represents an increase in functional, cross-linking activ-
ity of the enzyme. 
Using immunohistochemical and biochemical techniques, we 
have investigated the expression ofTgase-K enzyme activity, immu-
noreactivity, and mRNA in human skin treated with topical RA 
under occlusion for 4 d. The effects of RA on Tgase-K in vivo have 
been compared to those obtained in vitro with cultured human 
keratinocytes. 
MATERIALS AND METHODS 
Unless otherwise stated, all chemicals used were obtained from the 
Sigma Chemical Company, St. Louis, MO, and were of at least 
reagent grade. 
Tissue Samples Five hundred milligrams of 0.1 % RA cream 
(Retin-A, Ortho Pharmaceutical Corporation, Raritan, NJ) and its 
vehicle were applied to two areas of the buttock skin of normal 
volunteers and the two sites occluded with Saran Wrap for 4 d as 
previously described [19]. All subsequent biopsies were obtained 
under local, 1 % plain lidocaine, anesthesia. Keratome biopsies were 
obtained using an electric keratome set to a depth of 0.2 mm. Biop-
sies were immediately snap-frozen in liquid nitrogen and stored at 
-70° C until use. Four-millimeter punch biopsies taken for involu-
crin staining were placed in 10% f?r~alin and processed to,Paraffin, 
whereas bIOpSies for Tgase-K sta1l1111g were snap-frozen 111 hqUld 
nitrogen and stored at - 70° C until use. All subjects provided writ-
ten, informed consent and all procedures were performed under 
approval of the University of Michigan Medical Center Institu-
tional Review Board. 
Cell Cultures Single-cell suspensions of normal, human kerati-
nocytes were prepared from keratome biopsies of normal epidermis 
by trypsinization using 0.25% trypsin and 0.1 % ethylenediamine-
tetraacetic acid (EDTA) for 30 min at 30°C. Small, round viable 
cells were seeded onto, and grown in, 10 em diameter plastic dishes 
(Lux Flow Labs Inc., New York, NY) in a serum-free keratinocyte 
growth medium containing low calcium (modified MCDB 153) . 
Cells were maintained in a humidified incubator with 5% CO2/ 
95% air at 37°C and used between passages 2-4. Cells were treated 
at 50% confluence with either RA [1 f.,lM in dimethyl sulfoxide 
(DMSO)] or DMSO alone at a final concentration of 0.1 % for 4 d. 
Previous experiments had determined that 0.1% DMSO had no 
effect on keratinocyte growth or morphology. 
Measurement of Tgase Activity Tgase activity was measured 
using a modification of the technique of Yuspa et al [20]. In brief, 
frozen keratome biopsies were ground with a mortar and pestle and 
the powder suspended in homogenizing buffer (10 mM Tris, 
10 mM dithiothreitol, 0.5 mM EDTA pH 7.4) and homogenized 
in a glass homogen~zer. Resultant samples were centrifuged at 
150,000 X g for 40 min at 4°C. The supernatant was decanted and 
kept on ice. The pellet was resuspended in homogenizing buffer 
containing 1 % Triton X-100, incubated for 5 min at 37"C in order 
to solubilize the Tgase-K, and centrifuged as above to obtain a 
solubilized fraction. The efficiency of extraction by this procedure 
was found to be 70% ± 3% (n = 6). 
Twenty microliters of the sample (decanted supernatant for 
Tgase-C or solubilized fraction for Tgase-K) were added to 20 f.,ll of 
500 mM sodium borate (pH 9.5), 10 f.,ll of 10 mMEDTA (pH 7.5), 
20 f.,ll of casein (20 mg/ml), and 10 f.,ll of[3H] putrescine, and made 
up to 200 f.,ll with 110 f.,ll of distilled water. The subsequent reaction 
was conducted at 30°C for 30 min and terminated by the addition 
of 1 ml 10% TCA (4 ° C) containing 1 % putrescine. Precipitated 
THE JOURNAL OF INVESTIGATIVE DERMATOLOGY 
protein was collected on Whatman GF/C glass fiber filters . The 
filters were rinsed with 10 m110% TCA containing 1 % putresCIne 
dissolved in 0.5 ml protosol and counted in 10 mls of scintillation 
fluid. 
Protein was measured by the method of Bradford [21] using 
gamma-globulin as standard, and DNA content was measured by 
the method of Burton [22]. 
Immunohistochemical Staining of Transglutaminase and 
Involucrin: Immunoperoxidase Five-micrometer cryostat 
sections were placed on welled, glass slides and air dried. A~ter 
fixing in cold acetone, the sections were incubated for 45 min With 
a mouse monoclonal antibody to human Tgase-K [23] (BCl, Dr. S. 
M. Thacher, Texas A & M University) in a humidified chamber. 
After washing in phosphate-buffered saline (PBS), the sections were 
stained using a well-characterized avidin-biotin, immunoperoJ(l-
dase technique (Vectastain ABC, Vector Laboratories, Burlingame, 
CA), with 3-amino-9-ethyl carbazole as the chromogen. The seC-
tions were counterstained with 1 % hematoxylin. . 
Human keratinocytes grown in Lab-Tek chamber slides (Miles 
Inc., Elkhart, IN) were stained for Tgase-K in the same manner as 
for tissue sections following decanting of culture medium from the 
wells. 
Five-micrometer sections cut from formalin-fixed, paraffin-e~­
bedded specimens were stained using an antibody to involuc[1n 
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VOL. 99, NO.3 SEPTEMBER 1992 
ILl 5 <!l .... ~~ ~(J) 3 ~~ ~j:: 
... ~ 2 ~j:: i~ 1lI§ 1 9 0 ~.J. ~ 0 (J) VEHICLE 
8 
RA.1% 
RETINOIC ACID AND TRANSGLUTAMINASE 285 
The degree of epidermal staining with Tgase-K was assessed by 
light microscopy using a semiquantitative 1- 5 scale where 1 = 0-
20% of epidermis positive for Tgase-K; 2 = 21- 40%; 3 = 41-
60%; 4 = 61-80%; and 5 = 81-100% in five high power fields 
per individual. Involucrin staining was assessed in the same way. 
Dansylcadaverine Fluorescence Five-micrometer cryostat 
sections of biopsies from RA and vehicle-treated skin (n = 3) were 
examined for fluorescence using previously described dansylcada-
verine methodology, which identifies in situ enzyme activity 
[14 ,24J. Treated sections were examined using a Nikon microscope 
equipped with an appropriate excitation filter (DM 400) and emis-
sion filter (BA 460). 
Indirect Immunofluorescence Five-micrometer biopsy sec-
tions were incubated overnight with either affinity-purified rabbit 
antisera directed against human Tgase-C (Dr. V. Thomazy, Univer-
sity Medical School, Debrecen, Hungary) or BCl. Slides were 
washed twice in PBS, once in distilled water, and incubated with 
secondary antibody for 30 min at room temperature. For the Tgase-
C antibody, a fluorescein-conjugated swine-anti-rabbit antibody 
(Dako Corp., Carpinteria, CA) was used. For BCl (anti Tgase-K), a 
biotinylated goat-anti-mouse secondary antibody was used (Vector 
Laboratories, Burlingame, CA). After washing in PBS and distilled 
water, the slides were incubated for 30 min with Texas Red -
conjugated strepavidin (Gibco BRL). Following incllbation and 
washing, the slides were mounted in polyvinyl alcohol. Stained cells 
were observed with a Nikon Labophot fluorescence microscope 
equipped with a BZE filter (fluorescein) or G filter (Texas Red). 
Tgase-K mRNA Analysis Total RNA was prepared from kera-
tome biopsies of skin treated for 4 d under occlusion with RA (0.1 % 
cream) and its vehicle by cesium chloride gradient centrifugation as 
described [25J. RNA was size fractionated (40.ug/lane) on 1.2% 
formaldehyde-containing agarose gels and transferred to nylon 
membrane (Zetaprobe, Bio Rad Laboratories, Richmond, CA) by 
passive capillary action. Membranes were hybridized overnight 
with randomly labeled cDNA probes for human Tgase-K, human 
cellular retinoic acid-binding protein-II (CRABP-II) [26J, and 
human cyclophilin [27J at 42°C in STARK's buffer, salmon sperm 
DNA (10 mg/ml), and 10% dextran sulfate. Membranes were 
washed sequentially in 2 X SSC and 0.1 X SSC for 30 min at 55 ° C. 
Quantitation of mRNA bands was performed using a phosphor-
imager (Molecular Dynamics, Sunnyvale, CA). Data are expressed 
as counts hybridized to the transcripts for Tgase-K or CRABP-II 
divided by counts hybridized to the cyclophilin transcript. The band 
intensity of cyclophilin was used as an internal control for differ-
ences in sample loading. 
The human Tgase-K cDNA probe was cloned from a Agtll kera-
tinocyte library (Clontech, Palo Alto, CA), and contained 1.2 kb of 
the Tgase-K transcript, which had 100% homology to that de-
scribed by Polakowska [28J. A full description of the cloning of the 
Tgase-K cD NA will appear elsewhere. 
Statistical Analysis RA and vehicle effects on in vivo Tgase-K 
and involucrin immunoreactivity were compared using the Wil-
coxon signed rank test. All other comparisons were made with a 
paired student t test. 
Figure 2. Four-day RA treatment of normal skin causes increased TGase-K 
immunoreactivity. A , sections from normal human skin treated with vehicle 
(top pallel) and 0.1 % RA cream (bottom pallel) for 4 d were stained with 
monoclonal antibody Bel to Tgase-K. Visualization was by the immuno-
peroxidase method (X 230). B, semiquantitative assessment of Tgase-K 
immunoreactivity. The extent ofTGase-K epidermal staining was assessed 
in five high-power fields from individuals treated with retinoic acid (0.1 % 
cream) and its vehicle for 4 d. A 1- 5 semiquantitative scale was used with 5 
being maximum. Bars, means ± SEM. n = 18; vehicle versus RA p < 0.001. 
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Figure 4. RA reduces TGase-K staining in cultured human keratinocy~ 
Keratinocytes were treated with 0.1 % DMSO (top panel) or 1 fl-M . h 
in DMSO (bottom patlel) for 4 d. Cells were stained for TGase-K td 
BCl monoclonal antibody as described in Materials Qtld Met 10 s. 
(Magnification X 230.) 
----~---------------------------------------
Figure i Four-day RA treatment of normal skin increases involucrin 1(':; 
munoreactivity. A, sections from human skin treated with RA vehld7 1-
panel) and 0.1 % RA cream (bottom panel) were stained for involucrin. v~s)u~ 
ization was by the immunoperoxidase method (magnification X 23 .. i~ 
semiquantitative assessment of epidermal involucrin immunoreactiVity ed 
RA- and vehicle-treated skin. The extent of involucrin staining was as(~S~ 0/0 
in five high power fields from individuals treated for 4 d with ItA b "ng 
cream) and its vehicle. A semiquantitative 1 - 5 scale was used, with 55 el 
maximum. Bars, means ± SEM. n = 5; vehicle versus RA, p = 0.00 . 
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RESULTS 
Effect of Retinoic Acid on Tgase-K and Tgase-C Enzyme 
Act~vities In Vivo and In Vitro Four-day application of 0.1 % 
RA Increased cutaneous Tgase-K activity 2.8 times as compared to 
4-d treatment with vehicle alone (n = 12, P < 0.005). There was 
no significant difference in the activity of Tgase-C in human skin 
following treatment with 0.1 % RA or vehicle cream (n = 12, P = 
0.74), (Fig lA) . 
Conversely, 4-d incubation of cul tured keratinocytes with 111M 
RA produced a sixfold reduction in Tgase-K activity compared to 
Control (n = 4, P < 0.001). There was no significant difference in 
Tgase-c activity between RA-treated or control keratinocytes (Fig 
IB). 
Effect of Retinoic Acid on Tgase-K and Tgase-C Immuno-
reactivities In Vivo and In Vitro In vehicle-treated skin, 
Tgase-K immunoreactivity was limited to a thin, compact, immedi-
ately subcorneal band (Fig 2A), whereas in 0.1 % RA-treated skin, 
Tgase-K immunoreactivity was considerably expanded throughout 
the epidermis in a "chicken-wire" pattern (see Fig 2A). Using dan-
sylc~daverine, we observed expanded epidermal staining in RA but 
f,"0t In vehicle-treated skin (data not shown), a pattern similar to that 
.or the Tgase-K protein expression. Dansylcadaverine reactivity 
Indicates potential in situ enzyme activity ofTgase-K [14], implying 
that the observed increase in protein expression is associated with an 
I?creased content in vivo of active enzyme. Using a semiquantita-
tIVe scale from 1 to 5 there was a highly significant difference 
(p. < 0.001) between RA- and vehicle-treated skin (Fig 2B). Involu-
Crtn reactivity coincided exactly with the staining pattern seen for 
Tgase-K in vehicle- and RA-treated skin (Fig 3A), being signifi-
cantly increased in RA, compared to vehicle-treated skin (p = 
0.005, Fig 3B). In no skin sample was Tgase-C immunoreactivity 
observed. 
In contrast, treatment of cultured adult human keratinocytes for 
4 d with RA (111M) resulted in greatly diminished Tgase-K immu-
nOstaining (Fig 4). This is consistent with the observed decrease in 
Tgase-K activity in keratinocytes following 4-d RA treatment (Fig 
IB). 
Tgase_K mRNA Levels Previous reports have demonstrated 
that treatment of cultured keratinocytes with RA is associated with a 
reduction in Tgase-K mRNA levels [29J. This finding is consistent 
WI.th reduced Tgase-K activity in RA-treated keratinocytes and is 
eVidence suggesting that Tgase-K expression is, at least in part, 
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~igure S. Tgase-K and CRABP-II mRNA levels in epidermal biopsies 
/orn human skin treated with RA and its vehicle. A, total RNA was prepared 
v:ohrn keratome biopsies from 9 subjects treated with RA (0.1 % cream) and its 
Icle for 4 d under occlusion. Tgase-K mRNA was detected by Northern 
r~~llYSis (40,ug/lane) as described in Materials alld Methods. The amount of 
w Tgase-K cDNA probe that hybridized to the 2.9-kb Tgase-K transcript 
i a~ determined using a phosphorimager. The same RNA blot was hybrid-h\ to a cDNA probe for cyclophilin, and the amount of radioactivity 
phPdlzed to the Tgase-K mRNA band was normalized to that for cyclo-
eDlln. Vehicle vs RA, p = 0.14. B, the RNA blot was hybridized to the 
do NA probe for CRABP-II, and the data were analyzed and expressed as 
ne In A . Vehicle versus RA, p = 0.001. 
RETINOIC ACID AND TRANSGLUTAMINASE 287 
transcriptionally regulated [28,30J. Thus, one would expect that 
increased Tgase-K activity observed in RA-treated skin in vivo 
would be associated with elevated Tgase-K mRNA. Northern analy-
sis of total RNA prepared from paired biopsies of RA- and'vehicle-
treated skin, from nine individuals, revealed a small (78%) elevation 
in Tgase-K mRNA in RA- compared to vehicle-treated skin (Fig 
SA). This difference, however, was not statistically significant (p = 
0.14). To serve as a positive control, the same RNA blots used for 
measurement of Tgase-K mRNA were reprobed for CRABP-II 
mRNA (Fig 5B). It has recently been shown that the mRNA levels 
of CRABP-II are significantly elevated in skin following 4-d RA 
treatment [26]. As expected, CRABP-II mRNA was found to be 
significantly elevated (threefold, p < 0.002) after RA treatment, 
indicating that failure to observe increased Tgase-K mRNA in RA-
treated skin was not likely due to methodologic considerations. 
DISCUSSION 
This study demonstrates that short-term, occlusive application of 
RA to normal skin in vivo results in increased immunoreactivity and 
enzymatic activity ofTgase-K in conjunction with increased immu-
noreactivity of one of its substrates, involucrin. In contrast, RA 
reduces Tgase-K activity and immunoreactivity in cultured human 
keratinocytes. Rosenthal et al have also observed increased Tgase-K 
immunoreactivity in human skin treated with RA for J4 d [18]. 
Increased Tgase-K immunoreactivity has been reported in skin 
treated with RA for 16 weeks, although whether this represented an 
increase in functional, cross-linking activity of the enzume was not 
determined [17] . This study has shown that Tgase-K immunoreac-
tivity is elevated within 4 d of RA treatment and that this correlates 
with increased enzymatic activity, which suggests that the increased 
Tgase-K immunoreactivity observed in chronically RA-treated skin 
would also represent increased enzymatic activity. Other epidermal 
hyperproliferative states, such as psoriasis [31,32] and wound heal-
ing [33,34]' are also characterized by a suprabasal, precocious ex-
pression of Tgase-K immunoreactivity similar to our observations 
in RA-treated skin. Indeed, in psoriasis this increase in immunoreac-
tivity is concomitant with a significant elevation of enzyme activity 
[35J . 
We have confirmed previous in vitro observations that RA re-
duces Tgase-K activity in cultured keratinocytes. It has recently 
been demonstrated that after a 4-d application of 0 .1 % RA under 
occlusion, levels of RA in keratome biopsies are in the 1- 2-I1M 
range [36]. Thus, the concentration of RA (111M) used in in vitro 
keratinocyte culture work is pertinent to the situation observed in 
vivo. It is currently unknown why RA exerts a paradoxic effect on 
Tgase-K and other markers of terminal differentiation in vitro 
[16,37] compared to that seen in vivo. The differential effect cannot 
be explained by RA-induced toxicity or inhibition of keratinocyte 
growth in vitro as we did not observe cell death nor loss of viability. 
One explanation may be the presence of cytokines, growth factors, 
and other growth-modifying agents within the epidermis and espe-
cially the dermis in vivo. These agents could interact with RA, 
either directly or indirectly, via modulation of RA receptors and 
binding proteins, thereby modifying cellular responses to RA. In 
addition, the role of calcium in vivo is undetermined and fluxes in 
the intracellular and extracellular concentrations of this cation may 
also act to modulate cellular responses to RA. Lichti et al have 
reported that RA treatment of mouse keratinocytes in vitro will 
induce Tgase-C [5]; by contrast this was not the case in humans 
either in vitro or in vivo. The reason for this difference is unknown. 
Although the level of Tgase-K mRNA tended to be greater in 
RA- versus vehicle-treated skin, the difference between these two 
treatment groups failed to reach statistical significance. This was not 
due simply to variation in Tgase-K mRNA among the samples, 
because CRABP-II mRNA levels in the same samples could be 
shown, as expected [26], to be elevated significantly. It is possible 
that Tgase-K mRNA may have been transiently induced prior to the 
fourth day following RA treatment, when biopsies were taken for 
analysis. Alternatively, induction ofTgase-K activity in RA-treated 
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skin may involve predominently post-transcriptional or post-trans-
lational mechanisms that have been described in the regulation of 
keratin expression [38]. 
An increase in involucrin and Tgase-K in RA-treated skin would 
signify a maintenance of the cutaneous barrier function in long-
term treatment, an observation that would not have been predicted 
from purely in vitro studies with cultured human keratinocytes. 
The 4-d occluded retinoid bioassay [19] may prove to be a predictive 
model for the alterations in epidermal proliferation and differentia-
tion observed in chronic treatment of photoaging with RA cream. 
This model system also allows the implementation of functional 
biochemical assays, which require larger biopsy specimens than can 
be obtained in RA-treated facial or forearm photodamaged skin. 
We are grateful to Ted Hamiltoll, MS, for statistical allQlysis, Dale Yessian for 
secretarial assistallce, alld Rohill Gardtler for tissue procuremetlt. 
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